World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
49
Citations
9533
World Ranking
4331
National Ranking
182

Armando Gabrielli publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Armando Gabrielli sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 213 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Armando Gabrielli D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Armando Gabrielli sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 49 D-Index — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Armando Gabrielli is affiliated with Marche Polytechnic University in Italy and has an extensive publication record primarily in the field of Medicine, with a focus on several subfields including Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Rheumatology, Infectious Diseases, and Molecular Biology.

Their research has contributed notably to topics such as Systemic Sclerosis and Related Diseases, COVID-19 Clinical Research Studies, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Vasculitis and related conditions, Inflammasome and immune disorders, Extracellular vesicles in disease, and Systemic Lupus Erythematosus Research.

Armando Gabrielli has authored multiple recent papers, including the following:

  • Diagnosis and management of leukocytoclastic vasculitis, 2021, Internal and Emergency Medicine
  • Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients, 2020, Mechanisms of Ageing and Development
  • Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact, 2020, European Respiratory Journal
  • Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort, 2021, Journal of Autoimmunity
  • Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-associated spondyloarthritis, 2020, Lara D. Veeken

The frequent co-authors collaborating with Gabrielli include:

  • Devis Benfaremo (12 collaborations)
  • Giovanni Pomponio (8 collaborations)
  • Alessia Ferrarini (8 collaborations)
  • Silvia Svegliati (8 collaborations)
  • Michele Maria Luchetti (6 collaborations)

Their work is frequently published in the following venues:

  • Annals of the Rheumatic Diseases (7 publications)
  • Lara D. Veeken (4 publications)
  • Mechanisms of Ageing and Development (2 publications)
  • European Respiratory Journal (2 publications)
  • European Journal of Internal Medicine (2 publications)

Best Publications

  • 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

    Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson

  • Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

    Silvia Svegliati Baroni;Mariarosaria Santillo;Federica Bevilacqua;Michele Luchetti

  • Mapping and predicting mortality from systemic sclerosis

    Muriel Elhai;Christophe Meune;Marouane Boubaya;Jérôme Avouac

  • Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

    Jérôme Avouac;J. Fransen;U. A. Walker;V. Riccieri

  • A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

    S De Vita;L Quartuccio;M Isola;C Mazzaro

  • Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

    Suzana Jordan;Jörg H W Distler;Britta Maurer;Dörte Huscher

  • Risk of Non-Hodgkin Lymphoma in Celiac Disease

    Carlo Catassi;Elisabetta Fabiani;Giovanni Corrao;Maria Barbato

  • Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis

    Francesco Ciccia;Giuliana Guggino;Aroldo Rizzo;Riccardo Alessandro

  • Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease

    Silvia Svegliati;Attilio Olivieri;Nadia Campelli;Michele Luchetti

  • Imatinib for refractory chronic graft-versus-host disease with fibrotic features

    Attilio Olivieri;Franco Locatelli;Marco Zecca;Adele Sanna

  • Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.

    Maurizio Pietrogrande;Salvatore De Vita;Anna Linda Zignego;Pietro Pioltelli

  • Incidence and Characteristics of Non-Hodgkin Lymphomas in a Multicenter Case File of Patients With Hepatitis C Virus-Related Symptomatic Mixed Cryoglobulinemias

    Giuseppe Monti;Pietro Pioltelli;Francesco Saccardo;Mauro Campanini

  • European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

    R. Knobler;P. Moinzadeh;N. Hunzelmann;A. Kreuter

  • Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.

    Paola Sambo;Silvia Svegliati Baroni;Michele Luchetti;Paolo Paroncini

  • Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA)

    M. M. Luchetti;G. Piccinini;A. Mantovani;G. Peri

  • Bone marrow endothelial progenitors are defective in systemic sclerosis.

    Nicoletta Del Papa;Nadia Quirici;Davide Soligo;Cinzia Scavullo

  • Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.

    Carlo Chizzolini;Elena Raschi;Roger Michel Rezzonico;Cinzia Testoni

  • Preliminary classification criteria for the cryoglobulinaemic vasculitis

    S De Vita;F Soldano;M Isola;G Monti

  • Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases

    C.P. Denton;J.E. Pope;H.H. Peter;A. Gabrielli

  • Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts.

    Silvia Svegliati;Raffaella Cancello;Paola Sambo;Michele Luchetti

  • Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis

    Roberto Giacomelli;Gabriele Valentini;Felice Salsano;Paola Cipriani

  • Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies

    Martina Bonifazi;Irene Tramacere;Giovanni Pomponio;Barbara Gabrielli

  • Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis.

    Marialuisa Bocchino;Savina Agnese;Evelina Fagone;Silvia Svegliati

  • Management of Minor Head Injury in Patients Receiving Oral Anticoagulant Therapy: A Prospective Study of a 24-Hour Observation Protocol

    Vincenzo G. Menditto;Moira Lucci;Stefano Polonara;Giovanni Pomponio

  • Diagnosis and management of leukocytoclastic vasculitis

    Paolo Fraticelli;Devis Benfaremo;Armando Gabrielli

  • Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

    Attilio Olivieri;Michele Cimminiello;Paolo Corradini;Nicola Mordini

  • Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis

    Maria Giovanna Danieli;Lucia Calcabrini;Vincenzina Calabrese;Annalisa Marchetti

  • Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

    Paolo Fraticelli;Barbara Gabrielli;Giovanni Pomponio;Gabriele Valentini

  • Codeine, Ultrarapid-Metabolism Genotype, and Postoperative Death

    Armando Gabrielli;Enrico V. Avvedimento;Thomas Krieg

Frequent Co-Authors

Enrico V. Avvedimento
Enrico V. Avvedimento University of Naples Federico II
Christopher P. Denton
Christopher P. Denton University College London
Oliver Distler
Oliver Distler University of Zurich
Yannick Allanore
Yannick Allanore Université Paris Cité
Andrea Doria
Andrea Doria University of Padua
Marco Matucci-Cerinic
Marco Matucci-Cerinic University of Florence
Marco Candela
Marco Candela University of Bologna
Roberto Gerli
Roberto Gerli University of Perugia
Carlomaurizio Montecucco
Carlomaurizio Montecucco University of Pavia
Maurizio Cutolo
Maurizio Cutolo University of Genoa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology opens doors to various specialized healthcare roles, especially in nursing and practitioner programs focused on mental health and acute care. For those interested in psychiatric nursing, exploring the best pmhnp programs can help you find online options with strong clinical placement rates, ensuring valuable hands-on experience.

Cost is a significant factor for many students. Fortunately, there are some of the cheapest psychiatric nurse practitioner programs available that still maintain high educational standards, making advanced degrees more accessible without compromising quality.

Career pathways can vary widely in salary depending on specialization and geographic location. For example, understanding the dnp salary by specialty can guide you in choosing a focus area that aligns with your financial goals while leveraging your immunology background.

Many practicing nurses consider further specialization. If you are an FNP looking to advance your career, a bridge program such as the fnp to acute care np bridge program offers a structured pathway to make this transition smoothly, expanding your expertise into critical and acute care settings.

Best Scientists Citing Armando Gabrielli

Trending Scientists